Corcept Therapeutics Incorporated (CORT NASDAQ) stock market data APIs
$75.8277
-4.38(-5.8%)
as of September 17, 2025
Try our APIs with
free plan!
Corcept Therapeutics Incorporated Financial Data Overview
Price chart is built with
Anychart
Corcept Therapeutics Incorporated engages in discovery and development of medication for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of hypercortisolism; relacorilant combined with nab-paclitaxel which is in phase III clinical trial to treat platinum-resistant ovarian tumors; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; and for treatment for prostate cancer which is in phase II clinical trial. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; and miricorilant, which is in phase IIb trial for the treatment of metabolic dysfunction-associated steatohepatitis. The company was incorporated in 1998 and is headquartered in Redwood City, California.
Prev. Close
75.8277
Open
71.4456
High
75.3611
Low
70.9799
52 wk Range
40.62-117.33
Market Cap
7 515 M
P/E Ratio
63.6786
Shares Outstanding
105 M
Revenue
716 M
EPS
0.29
Beta
0.292
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Corcept Therapeutics Incorporated (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Corcept Therapeutics Incorporated data using free add-ons & libraries
Get Corcept Therapeutics Incorporated Fundamental Data
Corcept Therapeutics Incorporated Fundamental data includes:
- Net Revenue: 716 M
- EBITDA: 103 M
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-07-28
- EPS/Forecast: 0.1864
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Corcept Therapeutics Incorporated News
New
Corcept (CORT): Buy, Sell, or Hold Post Q2 Earnings?
Corcept trades at $69.52 per share and has stayed right on track with the overall market, gaining 20.1% over the last six months. At the same time, the S&P 500 has returned 16.5%. Is there a buying o...
Q2 Earnings Roundup: Corcept (NASDAQ:CORT) And The Rest Of The Branded Pharmaceuticals Segment
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Corcept (NASDAQ:CORT) and the best and wo...
Alger Russell Innovation Index Updates for Third Quarter 2025
NEW YORK, Sept. 15, 2025 /PRNewswire/ -- Fred Alger Management, LLC ("Alger"), a privately held growth equity investment manager, today announced the quarterly rebalancing of the Alger Russell Innovat...
11 fast-growing small-cap stocks that could get a boost from the Fed’s next move
`` Investors are anticipating that the Federal Open Market Committee will cut the federal-funds rate on Sept. 17. - MarketWatch photo illustration/iStockphoto `` Small-cap stocks have lagged behind l...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
